TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Lung Cancer Research Foundation Announces New Research Collaboration with Daiichi Sankyo and AstraZeneca

Friday, March 17, 2023

The Lung Cancer Research Foundation (LCRF) has made an important announcement regarding a collaborative effort with Daiichi Sankyo and AstraZeneca. This partnership aims to provide funding for up to three research grants focused on antibody drug conjugates (ADCs) with the goal of improving outcomes for individuals with lung cancer. Researchers and professionals in the field are invited to submit their applications for these grants, with the deadline set for May 31, 2023.

Lung cancer remains the leading cause of cancer-related deaths globally, affecting both men and women. In the United States alone, there are over 652 new diagnoses of lung cancer reported every day. Unfortunately, lung cancer often goes undetected until it reaches advanced stages, leading to more aggressive disease progression and poorer patient outcomes compared to cases diagnosed earlier. Additionally, there is a high incidence of disease recurrence following initial treatment.

ADCs offer a promising approach to cancer treatment as they are designed to specifically target cancer cells while minimizing damage to healthy cells. These compounds consist of a monoclonal antibody that recognizes a specific protein present on cancer cells and is attached to a potent cytotoxic agent known as the payload. ADCs have already demonstrated effectiveness and potentially more manageable toxicity profiles in several cancer types, thanks to the localized release of the cytotoxic payload directly within tumors. Encouraging results from early phase trials of ADCs in non-small cell lung cancer have further fueled interest in their potential applications.

Through this collaboration, the focus is on supporting research related to HER2 directed and TROP2 directed ADCs, including investigations into their mechanism of action, biomarkers, and resistance mechanisms. Katerina Politi, PhD, Chair of LCRF Scientific Advisory Board, expressed excitement about this grant program, emphasizing the importance of further studying ADCs and their potential application in lung cancer treatment. The field of ADCs holds great promise and presents an exciting avenue for lung cancer research.

The LCRF - Daiichi Sankyo - AstraZeneca Research Grant on Antibody Drug Conjugates will facilitate a deeper understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer, as well as HER2 directed ADCs in HER2 mutant non-small cell lung cancer (NSCLC) and primary and acquired resistance to TROP2 directed and HER2 directed ADCs. Researchers interested in applying for this two-year $270,000 award are required to submit their proposals by midnight on May 31, 2023, Eastern Time (ET). More information regarding eligibility, requirements, and deadlines can be found at LCRF.org/Funding.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit